4D Molecular Therapeutics Inc
FDMT7.100USD
+0.440+6.61%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
331.57MValor de mercado
PerdaP/L TTM
Mais detalhes de 4D Molecular Therapeutics Inc Empresa
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Informações da empresa
Código da empresaFDMT
Nome da Empresa4D Molecular Therapeutics Inc
Data de listagemDec 11, 2020
CEODr. David Kirn, M.D.
Número de funcionários227
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 11
Endereço5858 Horton Street #455
CidadeEMERYVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94608
Telefone15105052680
Sitehttps://4dmoleculartherapeutics.com/
Código da empresaFDMT
Data de listagemDec 11, 2020
CEODr. David Kirn, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Robert (Bob) Kim, M.D.
Dr. Robert (Bob) Kim, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
14.00K
0.00%
Netherlands
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: há 3 horas
Atualizado em: há 3 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
BlackRock Institutional Trust Company, N.A.
6.67%
The Vanguard Group, Inc.
5.86%
Outro
59.78%
Investidores
Investidores
Proporção
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
BlackRock Institutional Trust Company, N.A.
6.67%
The Vanguard Group, Inc.
5.86%
Outro
59.78%
Tipos de investidores
Investidores
Proporção
Investment Advisor
20.61%
Investment Advisor/Hedge Fund
19.76%
Hedge Fund
17.65%
Research Firm
14.80%
Venture Capital
14.73%
Individual Investor
3.85%
Sovereign Wealth Fund
0.12%
Bank and Trust
0.11%
Pension Fund
0.09%
Outro
8.28%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
351
46.37M
100.09%
-13.01M
2025Q1
358
46.38M
99.71%
-13.16M
2024Q4
357
49.60M
107.13%
-13.93M
2024Q3
350
60.77M
117.85%
-4.39M
2024Q2
340
60.30M
117.01%
-2.54M
2024Q1
324
59.47M
116.84%
+10.27M
2023Q4
284
45.54M
106.82%
-1.53M
2023Q3
275
45.63M
108.12%
-4.94M
2023Q2
263
44.82M
109.79%
-393.70K
2023Q1
254
34.42M
103.72%
-2.13M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BVF Partners L.P.
4.56M
9.85%
+1.89M
+70.79%
Mar 31, 2025
RA Capital Management, LP
4.56M
9.85%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
3.75M
8.09%
-81.59K
-2.13%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.53M
7.63%
-321.37K
-8.34%
Mar 31, 2025
The Vanguard Group, Inc.
2.76M
5.95%
-97.19K
-3.40%
Mar 31, 2025
Novo Holdings A/S
1.95M
4.21%
+450.00K
+30.00%
Mar 31, 2025
Janus Henderson Investors
1.89M
4.08%
-360.31K
-16.00%
Mar 31, 2025
Kirn (David)
1.66M
3.58%
-360.00
-0.02%
Apr 24, 2025
Federated MDTA LLC
1.24M
2.68%
+1.24M
+32944.58%
Mar 31, 2025
Millennium Management LLC
1.63M
3.53%
+213.26K
+15.01%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
